Inhibiting NNMT Expression Lowering the expression of the NNMT enzyme isnt anything new under the sun, as it is well-connected to several disease states: NNMT is implicated in various disease conditions such as metabolic disorders, neurodegenerative diseases and cancer, and tissue NNMT expression or plasma levels of its product MNA have been proposed as biomarkers for these conditions Other chronic metabolic diseases that are linked to NNMT expression include: Insulin resistance & diabetes Heart disease Kidney disease Liver disease Parkinsons disease Chronic inflammation Im not suggesting that 5-Amino 1MQ will directly lead to reducing your risk of any of the diseases above that time will come when researchers finally smarten up and start testing the peptide in human clinical trials
Weight-based dosing considerations Some protocols adjust dosing based on body weight
6-alpha-methylprednisolone (1 mg/kg intraperitoneally, once daily) was given alone which produced a considerable worsening and was completely eliminated with coadministration of BPC 157 10 g/kg intraperitoneally
Without proper sterile technique, injections carry an infection risk
Skin Laxity During Rapid Weight Loss One of the most common concerns among patients on GLP-1 therapies is skin quality
TB-500 also promotes angiogenesis similar to BPC-157, reduces inflammation through cytokine modulation, and appears to have cardioprotective effects
